Along with the Oncology Brothers, Paolo Tarantino, MD, explores how ESR1 mutations frequently co-occur with other molecular alterations and the importance of maximizing endocrine-based therapy before moving on to antibody-drug conjugates or chemotherapy.
Joshua K. Sabari, MD, evaluates the objective clinical outcomes of emerging targeted therapies for ES-SCLC, comparing them with second-line topotecan and CAV regimens, while discussing the potential of various compounds for platinum-sensitive vs platinum-resistant subgroups. He also considers the applicability of TIGIT immunotherapy, highlighting the need for robust clinical trial data on its safety and efficacy as both monotherapy and in combination, and he reflects on whether tiragolumab is more suited for chemotherapy-naive non–small cell lung cancer than for ES-SCLC, based on the phase 2 CITYSCAPE trial results.
Joshua K. Sabari, MD, discusses the antitumor activity of second-line lurbinectedin, noting an ORR of 45%, a median DOR of 6.2 months, and a median OS of 11.2 months in patients with relapsed SCLC, and emphasizes the need for further studies to validate these findings in those with longer chemotherapy-free intervals while considering factors that may lead to lurbinectedin’s use over chemotherapy in candidates for platinum rechallenge, as well as the potential role of G-CSFs for prophylaxis.
Chunhui Han, PhD, discusses the potential feasibility of the integration of Gallium 68 PSMA-11 in biology-guided radiotherapy for patients with prostate cancer with bony metastases.
Antoni Vilaseca Cabo, MD, discusses the rationale behind the phase 1 study evaluating the safety and efficacy of TAR-210 in patients with FGFR-altered high- and intermediate-risk non–muscle invasive bladder cancer.
Petros Grivas, MD, PhD, elaborates on some key unanswered questions on approaches to bladder cancer treatment he discussed with participants at a Case-Based Roundtable event.
Joe DePinto, MBA, discusses some of the key challenges to equitable access to cell and gene therapies, especially in underserved populations.
Along with the Oncology Brothers, Paolo Tarantino, MD, provides an overview of the phase 3 EMERALD study that evaluated the efficacy of elacestrant as a second-line treatment for ER+, HER2- MBC, particularly in patients with tumors harboring an ESR1 mutation.
Panelist discusses how the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer is evolving to address current unmet needs and offers clinical pearls to community oncologists for optimizing patient care in this rapidly changing field.
Evan Lipson, MD, discusses feedback he’s received from colleagues about responses in patients with melanoma.
Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.
Harry Erba, MD, PhD, discusses the specific substudies included in myeloMATCH.
Erika P. Hamilton, MD, discusses antibody-drug conjugates in multiple types of breast cancer, and when to use these drugs in sequence.
Noah S. Kalman, MD, MBA, discusses how oncologists can determine the best course of action for the treatment and management of a patient with thyroid cancer.
Barbara O’Brien, MD, discusses the background behind the phase 2 TBCRC049 study investigating the combination of tucatinib, trastuzumab, and capecitabine for the treatment of patients with HER2-positive breast cancer and leptomeningeal metastasis.
Jaime Merchan, MD, discusses the background and findings from the LITESPARK-013 trial of belzutifan for the treatment of patients with advanced clear cell renal cell carcinoma.
Joshua K. Sabari, MD, describes the mechanism of action of lurbinectedin as a synthetic alkaloid that binds to guanine residues in the minor groove of DNA, forming adducts that disrupt DNA repair mechanisms and promote apoptosis in cancer cells, noting that its action contrasts with traditional alkylating agents by specifically interfering with DNA-protein interactions and transcription processes.
Joshua K. Sabari, MD, evaluates the potential of ifinatamab deruxtecan in combination with atezolizumab, with or without platinum-based chemotherapy, as first-line induction or maintenance therapy in ES-SCLC, emphasizing that statistically significant end points such as improved PFS and OS would be essential for clinical application in this patient population.
Yanghee Woo, MD, discusses the details and lasting impact of the CROSS trial in the treatment of gastroesophageal junction and esophageal cancers.
Hatim Husain, MD, discusses how the implementation of proactive prophylaxis strategies for patients taking amivantamab, including prophylactic antibiotics, good skin hygiene, and insights from the phase 2 COCOON study, can help manage potential adverse effects and improve treatment outcomes.
Yanghee Woo, MD, provides an overview of the CROSS trial which focused on treating patients with gastroesophageal junction cancers.
Ariel Lopez-Chavez, MD, discusses the current approach to managing recurrent small cell lung cancer especially in patients who have progressed after first-line chemotherapy.
Elizabeth A. Brem, MD, discusses the familiarity of treatments among oncologists for patients with diffuse large B-cell lymphoma in a Case-Based Roundtable event.
Arnab Basu, MD, MPH, FACP, explains why sensitivity might be higher in urothelial cancer vs other genitourinary cancers.
Alessandra Ferrajoli, MD, discusses the importance of supportive care in the management of patients with chronic lymphocytic leukemia with comorbidities.
Joshua K. Sabari, MD, discusses the potential treatment synergies expected from combining MK-6070, a trispecific T-cell engager, with ifinatamab deruxtecan, noting that specific patient and disease factors (eg, tumor expression profiles and previous treatment responses) could influence the decision to pursue dual T-cell engager therapy in early clinical development.
Joshua K. Sabari, MD, discusses how the dosing schedule of ifinatamab deruxtecan offers advantages in terms of simplicity and treatment adherence vs topotecan and lurbinectedin, suggesting that it may enhance the overall quality of life for patients undergoing treatment for SCLC.
Binod Dhakal, MD, MS, discusses some of the next steps for evaluating ciltacabtagene autoleucel in multiple myeloma and the CARTITUDE-4 trial.
Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with transplant-ineligible multiple myeloma.
Craig A. Portell, MD, discusses the current standard of care for patients with relapsed/refractory mantle cell lymphoma and how sequencing therapies changed the landscape of mantle cell lymphoma treatment.